AppLovin Downgrade on Growth Uncertainty Sends Shares Lower

What happened

Bank of America downgraded AppLovin to Neutral, citing increased uncertainty around the company's ability to sustain 30% long-term revenue growth, after second-quarter results raised questions about a previously assumed source of baseline sequential growth. The stock dropped 5% to $321, reflecting mounting skepticism about the durability of Axon's monetization engine and the impact of tougher comparisons. This downgrade adds to a narrative already clouded by an active SEC probe into data practices and ongoing short-seller allegations, both of which have amplified headline risk. The Q2 results likely revealed that the net revenue per installation expansion may be decelerating, consistent with management's own warning that prior growth 'may not be indicative' as saturation sets in. At a P/E of 46.5x, the market is now pricing a significant reset, with the stock trading well below the previous base-case implied value of $480 and the attractive entry zone of $400.

Implication

Investors should view the BofA downgrade as a validation of the thesis that AppLovin's valuation was unsustainable without clear proof of enduring 30% growth. The Q2 results breaking the 'baseline sequential growth' assumption directly threatens the core investment case that Axon can keep expanding yield per install. Combined with the SEC probe and persistent headline risk, the stock's path to recovery now requires not only strong quarterly execution but also resolution of regulatory uncertainty. At $321, the stock trades below our prior $400 attractive entry, but until management demonstrates that monetization growth stabilizes and the SEC probe is resolved without operational constraints, we see no catalyst for re-rating. We maintain our WAIT rating and would look for further downside before considering a position, with the bear case of $330 now appearing more likely than the $480 base.

Thesis delta

The downgrade and Q2 concerns shift our thesis from a cautious 'wait for Q1 confirmation' to a more defensive posture. Previously, we saw an entry at $400 if Q1 results met guidance; now, with H1 2026 likely showing deceleration and the stock already at $321, the risk of further downside is elevated. We now view the bear case of $330 as the more realistic near-term scenario, and would only reconsider if the SEC probe resolves favorably and revenue growth stabilizes above 20%.